Insights into Physician's Perceptions of Levocloperastine's Safety and Efficacy in Children: An Online Survey in Clinical Practice

Abstract

Cough is a common symptom in pediatric patients, often requiring effective and well-tolerated antitussive treatments.
Although traditional agents like dextromethorphan and codeine are effective, they are associated with side effects like
drowsiness, nausea, and dependency risks. Levocloperastine (LCP), a nonopioid antitussive, has emerged as a safer alternative
with a dual mechanism of action targeting both central and peripheral pathways. This manuscript highlights the findings from
an online survey that gathered insights from Indian physicians regarding their perceptions of LCP's safety and efficacy in
children aged 2 to 15 years. The survey data came from 161 physicians through a structured electronic questionnaire. Results
indicated high physician confidence in LCP's rapid onset of action, tolerability, and minimal side effects. Notably, 86.6%
of participants prescribed LCP in their clinical practice to the children, with 69.6% finding it faster-acting than traditional
agents. Additionally, 80.7% reported reduced night-time sleep disruptions, and 96.9% found it well-tolerated in pediatric
patients. These findings align with existing literature and reinforce LCP's role as a preferred antitussive in pediatric cough
management.